Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2021 Nov 24;3(Suppl 1):6-10.
doi: 10.1002/jha2.338. eCollection 2022 Jan.

Overview of approved CAR-T therapies, ongoing clinical trials, and its impact on clinical practice

Salyka Sengsayadeth  1 , Bipin N Savani  1 , Olalekan Oluwole  1 , Bhagirathbhai Dholaria  1
Affiliations
Review

Overview of approved CAR-T therapies, ongoing clinical trials, and its impact on clinical practice

Salyka Sengsayadeth et al. EJHaem. .

Abstract

In recent years, we have seen rapid expansion of chimeric antigen receptor T-cell (CAR-T) therapies in multiple malignancies. CAR-T therapy has profoundly altered the treatment landscape of non-Hodgkin lymphoma, B-cell acute lymphoblastic leukemia, and multiple myeloma. Currently available CD19 and B-cell maturation antigen-directed CAR-T therapies have shown high overall response rate and durable remissions in patients who have failed standard therapies. Multiple studies are underway exploring the role of CAR-T-cell therapy as earlier line of treatment. In high-grade B-cell lymphoma, CD19 CAR-T therapy may replace autologous hematopoietic cell transplantation as second line therapy in near future. CAR-T-cell therapy targeting novel tumor-associated antigens will help expand utility of this treatment modality in other hematological malignancies. It may also help overcome limitations of currently approved CAR-T-cell therapies. In this review, we have provided an overview of currently approved CAR-T therapies and upcoming clinical trials which may potentially impact the clinical practice.

Keywords: CAR‐T cell therapy; acute lymphoblastic leukemia; diffuse large B‐cell lymphoma; multiple myeloma; non‐Hodgkin lymphoma.

PubMed Disclaimer

Conflict of interest statement

The authors declare that there is no conflict of interest that could be perceived as prejudicing the impartiality of the research reported.

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. King AC, Orozco JS. Axicabtagene ciloleucel: the first FDA‐approved CAR T‐cell therapy for relapsed/refractory large B‐cell lymphoma. J Adv Pract Oncol. 2019;10(8):878–82. - PMC - PubMed
    1. Neelapu SS, Locke FL, Bartlett NL, Lekakis LJ, Miklos DB, Jacobson CA, et al. Axicabtagene ciloleucel CAR T‐cell therapy in refractory large B‐cell lymphoma. N Engl J Med. 2017;377(26):2531–44. - PMC - PubMed
    1. Locke FL, Ghobadi A, Jacobson CA, Miklos DB, Lekakis LJ, Oluwole OO, et al. Long‐term safety and activity of axicabtagene ciloleucel in refractory large B‐cell lymphoma (ZUMA‐1): a single‐arm, multicentre, phase 1–2 trial. Lancet Oncol. 2019;20(1):31–42. - PMC - PubMed
    1. Nastoupil LJ, Jain MD, Feng L, Spiegel JY, Ghobadi A, Lin Y, et al. Standard‐of‐care axicabtagene ciloleucel for relapsed or refractory large B‐cell lymphoma: results from the US lymphoma CAR T consortium. J Clin Oncol. 2020;38(27):3119–28. - PMC - PubMed
    1. Jacobson CA, Chavez JC, Sehgal A, William BM, Munoz J, Salles GA, et al. Outcomes in ZUMA‐5 with axicabtagene ciloleucel (axi‐cel) in patients (pts) with relapsed/refractory (R/R) indolent non‐Hodgkin lymphoma (iNHL) who had the high‐risk feature of progression within 24 months from initiation of first anti‐CD20–containing chemoimmunotherapy (POD24). J Clin Ancol. 2021;39(15):7515.

LinkOut - more resources